261 F. Supp. 3d 307
D.R.I.2017Background
- Plaintiffs (Direct Purchasers, End-Payors, and Retailers) allege Warner Chilcott, Watson/Actavis, and Lupin conspired to delay generic entry for Loestrin 24 through settlements, side deals, and a product "hop" to Minastrin 24, causing supracompetitive prices.
- Key transactions: Watson Agreement (no-authorized-generic, 6-month exclusivity, promotional/co-promotion deals); Lupin Agreement (licenses to market other drugs, contingent deals, and payment for fees); similar settlement with Mylan.
- Plaintiffs allege the ’394 patent (claimed 23–25 day regimen) was procured/enforced by fraud (failure to disclose a 1993 human study, prior art including the Molloy reference, and misstatements about estrogen dosages) and that Warner Chilcott listed the patent in the FDA Orange Book knowing it was invalid/unenforceable.
- Warner Chilcott reformulated/withdrew Loestrin 24 and introduced Minastrin 24 (a chewable-labeling/insignificantly changed product) shortly before generic entry — alleged "product hop" (hard switch) to thwart substitution and impede generics.
- Procedurally: MDL consolidated; First Circuit vacated initial dismissal and remanded. On remand the district court denied most motions to dismiss (with limited exceptions) and dismissed parent companies (Allergan, Actavis) for insufficient allegations of post-acquisition liability.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Reverse-payment (non-cash) settlements — are the Watson and Lupin agreements large, unjustified reverse payments under Actavis? | Agreements (no-AG, promotional/licensing deals, exclusivity, acceleration clauses) together transferred substantial value to generics to induce delay and are not for fair value. | Many components are pro-competitive, common business arrangements, or payments from generic to brand; some components (e.g., acceleration clauses) are legitimate and not subject to antitrust scrutiny as a matter of law. | Plaintiffs plausibly alleged the components and the deals as a whole constituted large and unjustified reverse payments; claims survive 12(b)(6). |
| Walker Process / fraud on the PTO (procurement misconduct) — did applicants knowingly omit/misrepresent material information (1993 human study, Molloy, estrogen amounts)? | Applicants and subsequent Warner Chilcott personnel knew of and concealed material prior art and a negative human study; omission was material and intended to deceive the PTO. | Patent prosecution record and later claim construction undermine materiality; defendants contest intent and materiality. | Walker Process–style fraud allegations pleaded with sufficient particularity to survive dismissal; materiality and intent remain fact issues for discovery. |
| Sham litigation / Orange Book listing — were infringement suits and Orange Book listing objectively baseless and used to impede competition? | Given alleged fraud (Walker Process), enforcement and Orange Book listing were objectively baseless and used to block generics. | Noerr-Pennington protects patent litigation; enforcement of a patent (even aggressively) is usually immunized absent clear baselessness or fraud. | Sham litigation and improper Orange Book–listing theories survive at pleadings stage given plausible allegations of fraud and baseless suits. |
| Product hop (hard switch) — did Warner Chilcott’s withdrawal of Loestrin and introduction of Minastrin unlawfully maintain monopoly? | The withdrawal/launch constituted a hard switch that coerced prescribing behavior, deprived generics of the cost-efficient distribution/substitution base, and lacked legitimate procompetitive justification. | Product changes and discontinuations are legitimate business decisions and not per se anticompetitive; prior cases (including a Warner Chilcott win) distinguish lawful innovation. | Plaintiffs plausibly alleged an exclusionary hard switch; product-hopping claim survives dismissal. |
Key Cases Cited
- FTC v. Actavis, 570 U.S. 136 (2013) (held reverse-payment settlements are subject to rule-of-reason antitrust scrutiny)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading standard: plausibility required under Rule 8)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (antitrust pleading standard and Twombly plausibility/discovery principle)
- In re Loestrin 24 Fe Antitrust Litig., 814 F.3d 538 (1st Cir. 2016) (directed remand; guidance on pleading non-cash reverse payments and required showings)
- Walker Process Equip. v. Food Mach. & Chem. Corp., 382 U.S. 172 (1965) (patent procured by knowing fraud may give rise to antitrust liability)
- Prof’l Real Estate Investors, Inc. v. Columbia Pictures Indus., 508 U.S. 49 (1993) (standard for sham litigation exception to Noerr-Pennington)
- Eastman Kodak Co. v. Image Tech. Servs., 504 U.S. 451 (1992) (single-brand product markets can be properly defined in some circumstances)
- New York ex rel. Schneiderman v. Actavis PLC, 787 F.3d 638 (2d Cir. 2015) (product-hop/withdrawal + hard-switch analysis; preliminary injunction framework)
- Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011) (tightened standards for intent and but-for materiality in inequitable-conduct/intent-to-deceive PTO contexts)